Sensus scores Premier contract for brachytherapy

By staff writers

May 8, 2019 -- Superficial radiation therapy provider Sensus Healthcare has signed a group purchasing agreement for brachytherapy products with Premier, effective August 1.

The new agreement offers special pricing and prearranged terms for Premier members to buy the SRT-100 superficial radiation therapy systems from Sensus. SRT is designed to deliver precise, calibrated, low-dose radiation to eradicate basal and squamous cell carcinomas, as well as the nonmalignant tumor cells that cause keloids -- a type of rare scar that can develop from a piercing or tattoo. Each treatment is virtually painless and does not involve cutting, bleeding, stitching, or anesthesia, according to the company.

Sensus SRT-100 has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of both nonmelanoma skin cancers and keloids.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking